Avenue Therapeutics, Inc. (ATXI) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Alexandra MacLean.
ATXI tiene fecha de IPO 2017-06-27, 2 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $1.68M.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
